0.00Open2.30Pre Close0 Volume8 Open Interest5.00Strike Price0.00Turnover0.00%IV-1.50%PremiumDec 20, 2024Expiry Date2.34Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.24Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Sana Biotechnology Stock Discussion
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...
• $Repare Therapeutics (RPTX.US)$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $Chewy (CHWY.US)$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $UiPath (PATH.US)$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $Pure Storage (PSTG.US)$ +10.6% (In reaction to earnings)
• $Credo Technology (CRDO.US)$ +10.2% (In reaction ...
SANA announced an initial payment of 50M using Beam's Cas12b system.
It's great for Beam that Cas12b, which Beam doesn't use, is being asked for. The strangest thing is that SANA only needs Cas12b, not Base Editor. It's hard to understand! ?
No comment yet